Full-Time

Lead Cytopathologist

Posted on 8/21/2026

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

San Carlos, CA, USA

In Person

Up to 20% travel. Ability to work at the San Carlos office is strongly preferred.

MD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Machine Learning
HIPAA

Get referred to Intuitive Surgical

See people who can refer or advise you

Requirements
  • An MD or DO degree is required, along with board certification in pathology and fellowship training in cytopathology.
  • At least 5 years of experience in clinical cytopathology and rapid on-site evaluation (ROSE) is required.
  • Strong understanding of pathology workflows, sample preparation, and diagnostic criteria is required.
  • Familiarity with digital pathology and the ability to learn new digital workflows is required.
  • Ability to translate clinical insight into actionable guidance for non-clinical and technical teams is required.
Responsibilities
  • Provide expert pathology guidance across product development initiatives.
  • Work with consultant pathologists to support annotation, validation, and research activities.
  • Evaluate and annotate pathology images and data.
  • Oversee pathology data quality, consistency, and interpretability across diverse datasets.
  • Guide algorithm validation, ground-truth curation, and performance evaluation from a clinical perspective.
  • Contribute to product development roadmaps and clinical validation studies.
  • Participate in scientific research, publications, and presentations.
  • Represent pathology and clinical interests in cross-functional discussions.
Desired Qualifications
  • Prior experience in medical imaging annotation and digital pathology.
  • Involvement in research or validation of artificial-intelligence-based pathology tools.
  • Prior experience in diagnostics or healthcare technology.
  • Publications or presentations in computational pathology or artificial-intelligence applications.
  • Familiarity with machine-learning and artificial-intelligence workflows and dataset curation.
  • Experience with regulatory frameworks for medical data, including FDA, CE, and HIPAA.
  • Willingness to travel up to 20%.

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 19% to $2.89 billion, beating estimates again.
  • Intuitive raised 2026 da Vinci procedure growth guidance to 13.5%-15.5%.
  • Asia-Pacific demand supports Penang operations starting 2028 and 1,200 jobs by 2032.

What critics are saying

  • FDA Class II recalls in 2026 hit da Vinci X, Xi, and SP components.
  • US da Vinci growth slowed to 12% in Q2 2026, signaling elective-procedure deferral.
  • Medtronic's Hugo and other robotic entrants erode Intuitive's pricing power by 2027.

What makes Intuitive Surgical unique

  • Da Vinci 5 deepens Intuitive Surgical's installed-base moat; Q2 2026 placements hit 468.
  • Recurring instruments and accessories drove 85% of Q2 2026 revenue, stabilizing cash generation.
  • Penang facility in Malaysia expands manufacturing resilience for da Vinci instruments and electromechanical devices.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 23rd, 2026
Thermo Fisher vs Intuitive Surgical: which premium healthcare stock justifies valuation?

Thermo Fisher and Intuitive Surgical both delivered strong recent quarters, but their premium valuations rest on different foundations. Thermo Fisher's case depends on recovery in life sciences spending after the pandemic slowdown. The company's Life Sciences Solutions segment saw reported revenue climb 13% year-over-year, with organic revenue up 3%. The Analytical Instruments business returned to growth after nearly two years of weak demand, suggesting laboratory spending is normalising. Intuitive Surgical maintains its premium through business model strength. The company's non-GAAP gross profit margin reached 70.0%, whilst its non-GAAP operating margin expanded 330 basis points year-over-year to 42.1%. Recurring revenue streams constitute roughly 85% of total sales. Intuitive placed 468 da Vinci surgical units in fiscal Q2, marking 18% year-over-year growth, indicating continued hospital investment in robotic surgery platforms.

Yahoo Finance
Aug 19th, 2026
Abbott beats Q2 estimates with 13% sales growth as diagnostics surge 42%, while Intuitive Surgical posts 19% revenue rise

Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.

PR Newswire
Aug 17th, 2026
Intuitive leases 316,000-sq-ft facility in Penang to manufacture surgical instruments, create 1,200 jobs by 2032

Intuitive, the global leader in minimally invasive care and pioneer of robotic-assisted surgery, has signed a lease agreement with Penang Development Corporation for a new manufacturing facility in Malaysia. The 316,000-square-foot site in Bandar Cassia Technology Park will produce surgical instruments and electromechanical devices for Intuitive's da Vinci surgical system. The facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The investment reflects Intuitive's commitment to Asia Pacific, where its da Vinci systems have treated more than 2.5 million patients across 13 markets over two decades. The expansion aims to support growing demand for robotic-assisted surgery across the region and strengthen Penang's position as a MedTech manufacturing hub in Southeast Asia.

Yahoo Finance
Aug 16th, 2026
Oppenheimer upgrades Intuitive Surgical to 'Outperform' with $500 price target

Oppenheimer upgraded Intuitive Surgical from "Perform" to "Outperform" with a $500 price target, implying a 24.6% upside. The analysts expect the medtech company to maintain its leading position in robotic surgery despite increasing competition. Intuitive reported strong Q2 results, with revenue rising 18.5% year-over-year to $2.89 billion, surpassing analyst expectations. Non-GAAP earnings per share climbed 27.9% to $2.80, beating the $2.50 estimate. The company placed 468 da Vinci surgical systems and 55 Ion endoluminal systems during the quarter. Combined da Vinci and Ion procedures rose approximately 16% globally. Wall Street maintains a "Strong Buy" consensus rating on the stock, with 22 of 31 analysts recommending a strong buy. The consensus price target of $480.93 represents a 19.85% upside.

Yahoo Finance
Aug 12th, 2026
Intuitive Surgical's valuation barely budges despite two years of growth forecasts

Intuitive Surgical trades at $401.23, down 32% from its 52-week high and 15% over twelve months. The stock currently trades at 37.7 times trailing adjusted earnings. Analysts forecast earnings of $12.08 per share by 2027, bringing the multiple down to 33 times — only 13% lower despite two years of growth. Consensus projects 7% annual earnings growth and 9.7% revenue growth, suggesting margin compression ahead. Management raised its 2026 gross profit margin guidance to 68-69%. However, the company plans to extend instrument use limits starting in the first half of 2027 to lower procedure costs and boost adoption. Intuitive has not finalised pricing for this programme, creating uncertainty around 2027 estimates. The company will quantify the impact on its next earnings call.